# Aktis Oncology Inc. (AKTS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Technology / Communications Equipment. Price $27.05, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Aktis Oncology Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 155.8×**. Each dollar of revenue is priced at 155.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -5.7%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -939.1%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -980.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: 43.6%**. 43.6% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 19.8%**. Return on all capital, debt included, is 19.8%: comfortably above what that capital costs.
- **Return on assets: -28.5%**. Each dollar of assets produces -28.5% of profit.

## Growth
- **Revenue growth (1 yr): 336.9%**. Revenue grew 336.9% over the last year.
- **EPS growth (1 yr): 3.8%**. Earnings per share rose 3.8%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 2.4×**. It would take 2.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 7.37** (quick 7.37). Current assets cover the next year's liabilities 7.37 times.
- **Altman Z-score: 1.42**. A Z-score of 1.42 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Aktis Oncology Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Aktis Oncology Inc.; the consensus is strong_buy, with an average price target of $34.81 (+29% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -20.9%** (83.8% above the low). Trading 21% below its 52-week high.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 1.55** (volatility 69%). Beta of 1.55 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AKTS · Page: https://foliofundamentals.com/stocks/akts

Not investment advice.